Institution
Beatson West of Scotland Cancer Centre
Healthcare•Glasgow, Scotland, United Kingdom•
About: Beatson West of Scotland Cancer Centre is a healthcare organization based out in Glasgow, Scotland, United Kingdom. It is known for research contribution in the topics: Cancer & Population. The organization has 489 authors who have published 1031 publications receiving 41277 citations. The organization is also known as: Beatson Oncology Centre.
Topics: Cancer, Population, Gemcitabine, Prostate cancer, Radiation therapy
Papers
More filters
••
TL;DR: This work considers the current role of epoetin beta in the management of chemotherapy-related anemia and suggests a higher rate of thromboembolic events, enhanced tumor progression and reduced survival in patients with cancer who receive ESA therapy.
Abstract: Anemia is a common complication of systemic anti-cancer treatment. In this context epoetin beta, like other erythropoiesis-stimulating agents (ESAs), has demonstrable efficacy in raising Hb concentration and reducing the requirement for red cell transfusion. Consequently ESA therapy has gained increasing prominence in the management of chemotherapy-related anemia. However, recent trial data have suggested a higher rate of thromboembolic events, enhanced tumor progression and reduced survival in some patients with cancer who receive ESA therapy. In response, regulatory authorities have mandated increasingly restrictive label changes. In light of these new developments we consider the current role of epoetin beta in the management of chemotherapy-related anemia.
6 citations
••
TL;DR: Efti in combination with pembrolizumab is safe and shows encouraging antitumor activity in platinum pre-treated 2nd line HNSCC patients and the study was approved by ethics committees and institutional review boards.
Abstract: 6028Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) activation and CD8 T-cell activation. T...
6 citations
••
Beatson West of Scotland Cancer Centre1, Memorial Sloan Kettering Cancer Center2, Southampton General Hospital3, University of Nantes4, Peter MacCallum Cancer Centre5, Hammersmith Hospital6, Monash University, Clayton campus7, University of Manchester8, University of Bologna9, McGill University10, Institut Gustave Roussy11
6 citations
••
University of Manchester1, Guy's and St Thomas' NHS Foundation Trust2, Brighton and Sussex University Hospitals NHS Trust3, Torbay Hospital4, Weston Park Hospital5, University College London6, Cambridge University Hospitals NHS Foundation Trust7, University of Wolverhampton8, James Cook University Hospital9, Clatterbridge Cancer Centre NHS Foundation Trust10, Cardiff University11, Aberdeen Royal Infirmary12, Beatson West of Scotland Cancer Centre13
TL;DR: In this paper, the authors describe the changes that took place in the management of patients with stage I-III lung cancer from April to October 2020, which resulted in an increase in hypofractionation.
6 citations
••
University of Manchester1, University Hospital Southampton NHS Foundation Trust2, University College Hospital3, Papworth Hospital4, University College London Hospitals NHS Foundation Trust5, Beatson West of Scotland Cancer Centre6, University of Glasgow7, National Health Service8, Newcastle upon Tyne Hospitals NHS Foundation Trust9, University of Wolverhampton10, University of Edinburgh11, Royal Liverpool University Hospital12, University Hospitals Birmingham NHS Foundation Trust13, National Institutes of Health14, Aberdeen Royal Infirmary15, University College London16, Institute of Cancer Research17, The Royal Marsden NHS Foundation Trust18
TL;DR: In this article, the authors proposed an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies, such as neuroendocrine carcinoma.
Abstract: Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
6 citations
Authors
Showing all 491 results
Name | H-index | Papers | Citations |
---|---|---|---|
Stan B. Kaye | 92 | 449 | 35666 |
Tessa L. Holyoake | 65 | 272 | 18780 |
Jim Cassidy | 64 | 217 | 20828 |
John Bellamy Foster | 59 | 531 | 15649 |
James Paul | 59 | 252 | 13394 |
Hani Gabra | 53 | 200 | 23073 |
Iain A. McNeish | 52 | 228 | 17880 |
Richard H. Wilson | 50 | 188 | 8989 |
David K. Chang | 48 | 126 | 14460 |
Thomas J. Evans | 48 | 143 | 13144 |
Robert Jones | 46 | 262 | 16459 |
Nigel B. Jamieson | 44 | 131 | 10913 |
T.R. Jeffry Evans | 41 | 113 | 7283 |
Anthony J. Chalmers | 35 | 133 | 4254 |
Mhairi Copland | 33 | 121 | 4795 |